Nevro, which is awaiting approval for a spinal cord stimulation device that treats leg and back pain, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Nevro would command a fully diluted market value of $401 million.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
